💊 医薬品 A-Z 🧬 標的 🛠 ツール 📚 ガイド
全医薬品 薬物分類 治療領域 副作用
ガイド 用語集 年表
比較 薬物の体内の旅 薬物ファミリー
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Cevimeline Hydrochloride

CHEMBL2218917 Phase 4 承認済み Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
489.6 g/mol
LogP
—
Phase
4

Xerostomia in Sjogren's syndrome is the indication for cevimeline hydrochloride, the salt form of a muscarinic agonist that stimulates residual exocrine tissue to secrete saliva. Because the action is cholinergic, conditions aggravated by parasympathetic stimulation call for caution: asthma, narrow-angle glaucoma and cardiovascular disease are the situations named in the product literature. Adequate fluid intake accompanies treatment so that the stimulated glands have substrate to draw upon. The salt reproduces the receptor pharmacology of the parent compound without modifying it. The formulation is recorded with the formula C20H38Cl2N2O3S2 and a mass near 489.6 g/mol, and it is an approved small-molecule agent developed through the final clinical phase.

The hydrochloride salt formulation of cevimeline provides the same muscarinic agonist activity as the parent compound, used for xerostomia in Sjögren's syndrome. It should be used cautiously in patients with asthma, narrow-angle glaucoma, or cardiovascular disease, as cholinergic stimulation may worsen these conditions. Adequate fluid intake is recommended to maximize its salivary stimulant benefit.

分子量

489.6000 g/mol

TPSA

76.50 Ų

作用機序

A muscarinic acetylcholine receptor agonist with relative selectivity for the M3 subtype. Cevimeline stimulates M3 receptors on salivary and lacrimal gland epithelium, increasing exocrine secretion and relieving dry mouth and dry eyes. The same cholinergic stimulation accounts for sweating and nausea, and for the caution required in asthma, narrow-angle glaucoma and cardiovascular disease.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

機序

A muscarinic acetylcholine receptor agonist with relative selectivity for the M3 subtype. Cevimeline stimulates M3 receptors on salivary and lacrimal gland epithelium, increasing exocrine secretion and relieving dry mouth and …

2D構造

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
CC1OC2(CS1)CN1CCC2CC1.Cl.O

                

                

                
                

                    
InChI

                    
InChI=1S/C10H17NOS.ClH.H2O/c1-8-12-10(7-13-8)6-11-4-2-9(10)3-5-11;;/h8-9H,2-7H2,1H3;1H;1H2

                

                

                

                    
                    

                        
Molecular Formula

                        
C20H38Cl2N2O3S2

                    

                    
                    

                        
HBD / HBA

                        
3 / 7

                    

                    
                    

                        
回転可能結合数

                        
0

                    

                    
                    
                    

                        
重原子数

                        
29

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
よくある質問

                

                    
                    

                        
                        

                            
The hydrochloride salt formulation of cevimeline provides the same muscarinic agonist activity as the parent compound, used for xerostomia in Sjögren's syndrome. It should be used cautiously in patients with asthma, narrow-angle glaucoma, or cardiovascular disease, as cholinergic stimulation may worsen these conditions. Adequate fluid intake is recommended to maximize its salivary stimulant benefit.

                        

                    

                    

                    

                    
                    

                        
                        

                            
A muscarinic acetylcholine receptor agonist with relative selectivity for the M3 subtype. Cevimeline stimulates M3 receptors on salivary and lacrimal gland epithelium, increasing exocrine secretion and relieving dry mouth and dry eyes. The same cholinergic stimulation accounts for sweating and nausea, and for the caution required in asthma, narrow-angle glaucoma and cardiovascular disease.

                        

                    

                    

                    

                    

                        
                        

                            
Yes, Cevimeline Hydrochloride is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL2218917.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 73416227.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-08-20.




        


        
        
    


    



    
医学的免責事項

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.